A pilot study to assess flutamide monotherapy compared With maximal androgen blockade in metastatic prostate cancer
Not Applicable
Completed
- Conditions
- Prostate cancerCancer
- Registration Number
- ISRCTN92984394
- Lead Sponsor
- Schering-Plough Ltd (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 0
Inclusion Criteria
1. Histologically confirmed prostate carcinoma
2. Skeletal metastases on bone scan, with radiological conformation if appropriate, or typical sclerotic metastases on X-ray
3. Life expectancy >6 months
4. Suitable for treatment by any of the study therapies
5. No previous hormonal therapy
6. Not currently receiving corticosteroids, spironolactone or aminoglutethamide
7. Adequate renal and hepatic function
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method